Ipamorelin
Growth Hormone Secretagogues
£28.00per vial
Ipamorelin is a synthetic pentapeptide and a selective agonist at the growth hormone secretagogue receptor GHSR-1a, the ghrelin receptor. Laboratory work uses it to examine growth hormone pulsatility and ghrelin-receptor biology, where its selectivity profile separates it from broader-spectrum secretagogues.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
Ipamorelin cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 711.9 g/mol
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for Ipamorelin, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 711.9 g/mol
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- IP5604
Molecular weight source: PubChem CID 9831659.
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 99.1% |
| Identity | Mass spectrometry | Confirmed |
IP5604 · 2026-06-02
§04Compound details
Ipamorelin is a synthetic pentapeptide studied in controlled laboratory settings for its activity at the growth hormone secretagogue receptor GHSR-1a, the receptor natively bound by ghrelin. It is a G-protein coupled receptor agonist, and receptor engagement is examined through the phospholipase C and inositol trisphosphate second-messenger route characteristic of that receptor class.
The research interest in Ipamorelin is its selectivity. Earlier growth hormone releasing peptides such as GHRP-6 and GHRP-2 show measurable cross-activity at corticotroph and lactotroph pathways in the same models. Ipamorelin is examined specifically because that cross-activity is markedly lower, which makes it useful as an isolating tool in study designs where GHSR-1a activity needs to be separated from broader pituitary signalling.
Preclinical investigations examine Ipamorelin in hypothalamic-pituitary axis models, in ghrelin-receptor binding characterisation, and in bone and gastric motility research frameworks. It is catalogued here as a reference compound for laboratory research. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Ipamorelin is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue, not issued on request afterwards.
Research Use Only
Ipamorelin is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Ipamorelin. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Ipamorelin relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Ipamorelin cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
Ipamorelin is a synthetic pentapeptide studied in controlled laboratory settings for its activity at the growth hormone secretagogue receptor GHSR-1a, the receptor natively bound by ghrelin. It is a G-protein coupled receptor agonist, and receptor engagement is examined through the phospholipase C and inositol trisphosphate second-messenger route characteristic of that receptor class.
The research interest in Ipamorelin is its selectivity. Earlier growth hormone releasing peptides such as GHRP-6 and GHRP-2 show measurable cross-activity at corticotroph and lactotroph pathways in the same models. Ipamorelin is examined specifically because that cross-activity is markedly lower, which makes it useful as an isolating tool in study designs where GHSR-1a activity needs to be separated from broader pituitary signalling.
Preclinical investigations examine Ipamorelin in hypothalamic-pituitary axis models, in ghrelin-receptor binding characterisation, and in bone and gastric motility research frameworks. It is catalogued here as a reference compound for laboratory research. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
Ipamorelin is listed as a pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue, not issued on request afterwards.
Compliance Notice
Research Use Only
Ipamorelin is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Ipamorelin. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Ipamorelin relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Ipamorelin cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. Ipamorelin is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Selective activity at the growth hormone secretagogue receptor GHSR-1a, in laboratory endocrine and ghrelin-biology models. Findings are preclinical.
It acts as an agonist at GHSR-1a, the ghrelin receptor, a G-protein coupled receptor. Receptor engagement is studied through the phospholipase C second-messenger route.
In comparable models it shows markedly lower cross-activity at corticotroph and lactotroph pathways than earlier growth hormone releasing peptides such as GHRP-6 and GHRP-2. That separation is what makes it useful as an isolating research tool.
Pre-mixed liquid in a sealed 3ml vial, at 5mg and 10mg. It is not a lyophilised powder and needs no preparation before laboratory use.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
